The Synergo system is indicated for Non-muscle Invasive Bladder Cancer (NMIBC), also known as Superficial Transitional Cell Carcinoma of the Urinary Bladder. The tumor is defined superficial as long as it is limited to the very internal layers of the bladder (those in direct contact with the urine). Your urologist should decide if your specific case is eligible for Synergo treatment after performing biopsies from those bladder layers.